Osteoporosis.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 96
- Publication type:
- Article
Works matching IS 1082801X AND DT 2005 AND VI 40 AND IP 3
Results: 19
1
2
Prior lack of efficacy with etanercept does not predict lack of efficacy with infliximab.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 93
- Publication type:
- Article
3
Crawford nominated for permanent FDA commissioner role.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 94
- Publication type:
- Article
4
Focus on...exenatide: a novel incretin mimetic hormone for the treatment of type 2 diabetes.
- Published in:
- 2005
- By:
- Publication type:
- Journal Article
5
Formulary issues and trends. The use of virtual expert panels: formulary decision-making in the 21st century.
- Published in:
- 2005
- By:
- Publication type:
- Journal Article
6
Selected literature.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 96
- Publication type:
- Article
7
Extended drug review cycle stipulated in final Medicare formulary guidance.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 95
- Publication type:
- Article
8
USP submits final Medicare Drug Benefit Model Guidelines.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 94
- Publication type:
- Article
9
Generic drug purchases, not importation, best means of lowering consumer costs.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 94
- Publication type:
- Article
10
Cardiac death risk 5x greater with concurrent oral erythromycin and CYP3A inhibitors.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 77
- Publication type:
- Article
11
FDA actions in brief.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 74
- Publication type:
- Article
12
Ziprasidone and risperidone equally efficacious for treatment of acute exacerbation of schizophrenia or schizoaffective disorder.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 92
- Publication type:
- Article
13
ACE inhibitors that penetrate the blood-brain barrier may slow Alzheimer's progress.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 91
- Publication type:
- Article
14
ACE inhibitors reduce all-cause mortality in diabetic nephropathy; data unclear for AIIRAs.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 91
- Publication type:
- Article
15
Exenatide.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 86
- By:
- Publication type:
- Article
16
The use of virtual expert panels: formulary decision-making in the 21st century.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 78
- By:
- Publication type:
- Article
17
FDA advisory committees recommend marketing of COX-2 inhibitors with 'black box' warning.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 76
- Publication type:
- Article
18
Drug and Formulary Trends.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 75
- Publication type:
- Article
19
FDA Drug Approvals.
- Published in:
- Formulary, 2005, v. 40, n. 3, p. 74
- Publication type:
- Article